KYORIN Pharmaceutical (4569) · InitiativeAchieved
KRP-AM1977Y Marketing Authorization Application
First written in FY2020-Q3. 1 of 2 entries say "Achieved", first in FY2021-Q3. Latest entry: FY2021-Q3.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Marketing authorization obtained for KRP-AM1977YA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2021-Q3AchievedAnnual report
「Regarding domestic development during the consolidated accounting period of the third quarter, marketing authorisation was obtained in November 2020 for Lasvic Intravenous Infusion Kit 150 mg, a new quinolone-class injectable antibacterial.」
Marketing authorisation was obtained for the new quinolone-class injectable antibacterial corresponding to KRP-AM1977Y. - FY2020-Q3First statedAnnual report
「We submitted a marketing authorization application for KRP-AM1977Y in October of that year.」
A marketing authorization application was submitted for the injectable quinolone antibacterial agent KRP-AM1977Y in October 2019.